In April 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance titled “Roadmap to Reducing Animal Testing in Preclinical Safety Studies,” outlining its commitment to advancing New Approach...more
GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management (e.g., Wegovy®) and are now being explored for treating a wide range of health...more
On January 6, 2025, the U.S. Food and Drug Administration (FDA) released draft guidance titled Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products...more
1/16/2025
/ Artificial Intelligence ,
Clinical Trials ,
Compliance ,
Digital Health ,
Draft Guidance ,
Food and Drug Administration (FDA) ,
Intellectual Property Protection ,
Machine Learning ,
Patents ,
Pharmaceutical Industry ,
Popular ,
Regulatory Requirements ,
Risk Management ,
Trade Secrets
The use of artificial intelligence (AI) to advance stem cell therapy has produced exciting results, with a key role in driving recent growth and innovation. Separated into three parts, this article provides an overview the...more
10/24/2023
/ Alice/Mayo ,
Artificial Intelligence ,
Biotechnology ,
Innovation ,
Intellectual Property Protection ,
Inventions ,
Patent Act ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Safeguards Rule ,
Stem cells